Skip to content
value.today

FLX Bio, Inc.

Total raised
$317 M
5 rounds on record
Latest round
$150 M
Dec 2024
First round on record
Apr 2016
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of FLX Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$150 MNo. 5$50 to $250 million

FLX Bio, Inc.: Raise no. 5, Dec 2024

Investors in this round

20 investors had bought by the notice of Jan 3, 2025: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for FLX Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$150 M of $150 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$6,498,827
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Wong · Executive Officer, Director
  • Dirk J. Brockstedt · Executive Officer
  • Rodney J. Young · Executive Officer
  • William J. Ho · Executive Officer
  • Linda J. Kozick · Director
  • Lori V. Lyons-Williams · Director
  • Mary Ann V. Gray · Director
  • Michael Giordano · Director
  • Wendye J. Robbins · Director
  • William J. Rieflin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Leerink Partners LLC (CRD 39011) · Boston, MassachusettsSold in all US states

Remarks in the notice

  • On the amounts: “The Total Offering Amount and Total Amount Sold includes the exercise price of $0.0001 per share, payable on the exercise of the warrants by the investors.”

Signed by Rodney Young, Cfo. Source: SEC Form D, newest notice filed Jan 3, 2025. Read the notice at the SEC.

equity, optionsSEC
May 2022$50 MNo. 4$50 to $250 million

FLX Bio, Inc.: Raise no. 4, May 2022

Investors in this round

1 investor had bought by the notice of Jun 3, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for FLX Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Wong · Executive Officer, Director
  • Dirk F. Brockstedt · Executive Officer
  • Rodney J. Young · Executive Officer
  • William F. Ho · Executive Officer
  • Linda J. Kozick · Director
  • Lori V. Lyons-Williams · Director
  • Mary Ann V. Gray · Director
  • Michael F. Giordano · Director
  • Wendye F. Robbins · Director
  • William J. Rieflin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount and the total amount sold include the exercise price, $0.0001 per share, payable on the exercise of the warrants by the investor.”

Signed by Rodney Young, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 3, 2022. Read the notice at the SEC.

optionsSEC
Dec 2018$37 MNo. 3$10 to $50 million

FLX Bio, Inc.: Raise no. 3, Dec 2018

Investors in this round

24 investors had bought by the notice of Jun 20, 2019: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for FLX Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$37 M of $67 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Wong · Executive Officer, Director
  • David F. Wustrow · Executive Officer
  • Dirk F. Brockstedt · Executive Officer
  • Eric F. Hall · Executive Officer
  • Paul F. Kassner · Executive Officer
  • William F. Ho · Executive Officer
  • Beth V. Seidenberg · Director
  • David V. Goeddel · Director
  • Linda J. Kozick · Director
  • Michael F. Giordano · Director
  • William J. Rieflin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian Wong, M.D., Ph.D., Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 20, 2019. Read the notice at the SEC.

equitySEC
Dec 2017$30 MNo. 2$10 to $50 million

FLX Bio, Inc.: Raise no. 2, Dec 2017

Investors in this round

10 investors had bought by the notice of Jan 4, 2018: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for FLX Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $60 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Wong · Executive Officer, Director
  • Rekha J. Hemrajani · Executive Officer
  • Beth Seidenberg · Director
  • David Goeddel · Director
  • Linda J. Kozick · Director
  • William J. Rieflin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian Wong, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 4, 2018. Read the notice at the SEC.

equitySEC
Apr 2016$50 MNo. 1$50 to $250 million

FLX Bio, Inc.: Raise no. 1, Apr 2016

Investors in this round

9 investors had bought by the notice of May 5, 2016: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for FLX Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Wong · Executive Officer, Director
  • Rekha J. Hemrajani · Executive Officer
  • Tim J. Lin · Executive Officer
  • Beth Seidenberg · Director
  • David Goeddel · Director
  • William J. Rieflin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian Wong, President. Source: SEC Form D, newest notice filed May 5, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • FLX Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2025).

    SEC Form D · Jan 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2025

That is all the official record says: FLX Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

13 named in official filings. Open an investor to see everything it has backed.

Investors in FLX Bio, Inc.
InvestorKindAmountRoundRoleSource
Column Group II GP, LPFund or asset managernot statednot statedHeld Series A, B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Column Group II, LPFund or asset managernot statednot statedHeld Series A, B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Column Group II Management, LPFund or asset managernot statednot statedHeld Series A, B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Kleiner Perkins Caufield & Byers XV, LLCOthernot statednot statedHeld Series A, B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
KPCB XV Associates, LLCOthernot statednot statedHeld Series A, B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
KPCB XV Founders Fund, LLCFund or asset managernot statednot statedHeld Series A, B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
LG Management, LLCFund or asset managernot statednot statedHeld Series B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Ponoi Capital II, LPFund or asset managernot statednot statedHeld Series A, B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Ponoi Capital, LPFund or asset managernot statednot statedHeld Series A, B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Ponoi II Management, LLCFund or asset managernot statednot statedHeld Series A, B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Ponoi Management, LLCFund or asset managernot statednot statedHeld Series A, B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Topspin Biotech Fund II, L.P.Fund or asset managernot statednot statedHeld Series B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Topspin Fund L.P.Fund or asset managernot statednot statedHeld Series B, C and C-2 preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 24 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by FLX Bio, Inc.
NameRoleNamed in
Brian WongExecutive officerJan 2025
Dirk J. BrockstedtExecutive officerJan 2025
Rodney J. YoungExecutive officerJan 2025
William J. HoExecutive officerJan 2025
Dirk F. BrockstedtExecutive officerJun 2022
William F. HoExecutive officerJun 2022
David F. WustrowExecutive officerJun 2019
Eric F. HallExecutive officerJun 2019
Paul F. KassnerExecutive officerJun 2019
Rekha J. HemrajaniExecutive officerJan 2019
Tim J. LinExecutive officerMay 2016
Brian WongDirectorJan 2025
Linda J. KozickDirectorJan 2025
Lori V. Lyons-WilliamsDirectorJan 2025
Mary Ann V. GrayDirectorJan 2025
Michael GiordanoDirectorJan 2025
Wendye J. RobbinsDirectorJan 2025
William J. RieflinDirectorJan 2025
Michael F. GiordanoDirectorJun 2022
Wendye F. RobbinsDirectorJun 2022
Beth V. SeidenbergDirectorJun 2019
David V. GoeddelDirectorJun 2019
Beth SeidenbergDirectorJan 2018
David GoeddelDirectorJan 2018